title: Targeted therapies: Role of sorafenib in HCC patients with compromised liver function.
authors.affiliation: Clinical Trials Unit, National Cancer Institute-G.Pascale Foundation, Napoli, Italy. dimaiomax@libero.it
authors.forename: Massimo
authors.initials: M
authors.lastname: Di Maio
authors.forename: Bruno
authors.initials: B
authors.lastname: Daniele
authors.forename: Francesco
authors.initials: F
authors.lastname: Perrone
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000473:pathology* / Q000628:therapy*; D017326:Clinical Trials, Phase III as Topic; D005355:Fibrosis / Q000473:pathology; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology* / Q000628:therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D017410:Practice Guidelines as Topic; D011725:Pyridines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000077157:Sorafenib; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib
references.citation: N Engl J Med. 2008 Jul 24;359(4):378-90
references.pmid: 18650514
references.citation: Lancet Oncol. 2009 Jan;10(1):25-34
references.pmid: 19095497
references.citation: J Clin Oncol. 2009 Apr 10;27(11):1800-5
references.pmid: 19255312
references.citation: Oncologist. 2009 Jan;14(1):95-100
references.pmid: 19144678
references.citation: Br J Surg. 1973 Aug;60(8):646-9
references.pmid: 4541913
references.citation: Oncologist. 2009 Jan;14(1):70-6
references.pmid: 19144684
references.citation: J Clin Gastroenterol. 2009 May-Jun;43(5):489-95
references.pmid: 19247201
references.citation: J Natl Cancer Inst. 2008 May 21;100(10):698-711
references.pmid: 18477802
references.citation: Oncologist. 2009 Jan;14(1):67-9
references.pmid: 19147690